Regidron, 20 pcs.

Pharmacotherapeutic group
Rehydration drug for oral administration.
ATC code
A07CA
Pharmacological properties
Pharmacodynamics
Medicinal product Regidron® is used for correction of electrolytes and fluid loss during diarrhea. Dextrose promotes electrolyte absorption, which contributes to the correction of metabolic acidosis. Osmolarity of the solution is 282 mosm/l, pH – 8.2.
Pharmacokinetics
Pharmacokinetic properties of water, electrolytes and dextrose contained in the drug are similar to those in the human body.

Indications

Active ingredient

Composition

The drug is a glucose-electrolyte mixture, which contains (per 1 bag): sodium chloride – 3.5 g, potassium chloride – 2.5 g, sodium citrate dihydrate – 2.9 g, dextrose – 10.0 g. The solution obtained by dissolving 1 sachet in 1 liter of water contains the following concentrations of active ingredients:

Sodium chloride 59.9 mmol

Potassium chloride 33.5 mmol

Sodium citrate dihydrate 9.9 mmol

p> Dextrose 55.5 mmol

Na+ 89.6 mmol

K+ 33.5 mmol

Cl- 93.4 mmol

Citrate 9.9 mmol

How to take, the dosage

The contents of one sachet are dissolved in 1 liter of freshly boiled cool drinking water. The resulting colorless solution is taken orally (orally). If necessary, the solution may be administered through nasogastric tube (in hospital conditions).

The prepared solution must be kept in a refrigerator (at +2 to +8 ° C), it should be consumed within 24 hours. No other ingredients should be added to the solution so as not to impair the effect of the drug.

Patients should be weighed before starting treatment to assess weight loss and degree of dehydration.

Patient nutrition or breastfeeding should not be interrupted during oral rehydration therapy, or should be continued immediately after rehydration. During treatment with the drug it is recommended to avoid eating foods rich in fats and simple carbohydrates (this may aggravate diarrhea).

In order to prevent dehydration the use of Rehydron® preparation should be started as soon as diarrhea begins. Usually it is necessary to use the drug for not more than 3-4 days; treatment is stopped when the diarrhea comes to an end. If nausea or vomiting has occurred, the solution should preferably be taken chilled in small portions (e.g. teaspoons).

Fluid replenishment

For fluid replenishment, Rehydrone® is taken during the first few days./sup> is taken during the first 6-10 hours in an amount that is twice the weight loss caused by the diarrhea. For example, if the weight loss is 400 g, the volume of Regidron® solution is 800 ml. During this phase, the use of other liquids is not required. It is not recommended to take food during the first 4 hours of fluid replenishment. If large amounts are taken, vomiting may occur.

Prevention of dehydration

If the diarrhea persists, after dehydration correction it is advisable to take Rehydron® and water for 24 hours according to the following scheme:

Body weight (kg)

Total/p>

amount of fluid required (l)

Rehydron (ml)

/p>

Water (ml)

Other

fluids (ml)

/p>

40-49

2.10

900

540

660

50-59

2.30

1000

600

700

60-69

2.50

1100

660

740

70-79

2.70

1200

720

780

80-89

3.20

1400

800

1000

90-99

3.60

1500

900

1200

Interaction

It has not been studied. The drug solution has a slightly alkaline reaction, so it may affect drugs whose absorption depends on the pH of the intestinal contents. Diarrhea itself may alter absorption of many drugs that are absorbed in the small or large intestine, or drugs whose metabolism has intestinal-hepatic circulation.

Special Instructions

In children, other solutions with lower sodium content and osmolarity should be used.

In view of the composition of the drug, caution should be exercised in patients with diabetes mellitus, impaired liver or renal function, and in patients on a diet low in salt (sodium and/or potassium).

In patients with diabetes mellitus, renal insufficiency, and some other chronic diseases, diarrhea can cause significant impairment of fluid or glucose balance. Because of this, treatment of diarrhea in these patients may require laboratory monitoring and hospitalization.

If the patient’s need for additional electrolytes is not confirmed by laboratory tests, the recommended doses of the drug should not be exceeded.

Severe dehydration (weight loss of >10 %, loss of urine excretion) should be treated with the help of intravenous rehydration therapy, after which the use of Rehydron® solution is allowed.

If intravenous administration of the drugs is necessary or if there is severe dehydration or severe vomiting, decrease or cessation of urine excretion, Rehydron® should be used with caution.

In case of vomiting, wait 10 minutes after the end of the vomiting attack and allow the solution to be drunk slowly, in small sips.

The patient should consult a physician if the following situations occur while using Rehydron®:

– sluggish speech, irritability, rapid fatigue, drowsiness, stupor;

– temperature rises above 39C;

– bloody stools;

– persistent vomiting;

– diarrhea lasts more than 2 days;

– severe abdominal pain.

The use of Rehydron® solution to replenish salt loss in diarrhea-associated cholera and a number of other severe intestinal infections may not be sufficient.

Persons with renal insufficiency or who are on a low potassium diet should be aware that the drug contains potassium.

Impact on ability to drive and operate machinery

It does not affect the ability to drive and engage in other potentially dangerous activities requiring increased concentration and quick psychomotor reactions.

Contraindications

Hypersensitivity to the components of the drug. Severe dehydration.

Coma (unconsciousness). Intestinal obstruction.

Serious vomiting.

Diarrhea due to cholera. Glucose-galactose malabsorption.

Side effects

In patients with normal renal function, the risk of hypernatremia (increased sodium in the blood) or excessive water intake is low. Vomiting may occur if taken too quickly.

Overdose

If a large volume or highly concentrated solution of Rehydron® is administered (if the solution is not prepared properly), hypernatremia (increased sodium content in the blood) may occur. Symptoms of hypernatriemia include weakness, neuromuscular agitation, drowsiness, confusion, coma, sometimes even respiratory arrest. In patients with decreased renal function, hyperkalemia (increased potassium in the blood) may occur, manifesting as an abnormal heart rhythm, weakness.

In case of symptoms of overdose a physician should be consulted. Water-electrolyte balance correction should be carried out on the basis of laboratory examination data.

Pregnancy use

In recommended doses Regidron® can be used during pregnancy and lactation.